The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 08, 2015

Filed:

Jan. 23, 2014
Applicants:

Technische Universität Graz, Graz, AT;

Karl-franzens-universität Graz, Graz, AT;

Inventors:

Martina Schweiger, Graz, AT;

Matthias Romauch, Graz, AT;

Robert Zimmermann, Graz, AT;

Nicole Mayer, Graz, AT;

Rolf Breinbauer, Graz, AT;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07C 69/94 (2006.01); C07C 229/52 (2006.01); C07C 69/78 (2006.01); C07D 231/18 (2006.01); C07D 231/14 (2006.01); C07C 65/24 (2006.01); C12Q 1/44 (2006.01);
U.S. Cl.
CPC ...
C07C 229/52 (2013.01); C07C 65/24 (2013.01); C07C 69/78 (2013.01); C07C 69/94 (2013.01); C07D 231/14 (2013.01); C07D 231/18 (2013.01); C12Q 1/44 (2013.01);
Abstract

A compound of formula (I) as defined herein is useful in the treatment and prevention of a disorder such as cachexia, stroke, atherosclerosis, coronary artery disease, and diabetes and pharmaceutical compositions of the same. Also, a method of screening for lipase inhibitors using a compound of formula (I) and determining its lipase inhibitory activity. The method includes in vitro assays of compounds using ATGL and/or HSL, and cellular assays wherein inhibition is followed by observing indicators of efficacy. Also, methods for treatment or prevention of a condition involving cachexia, stroke, artherosclerosis, coronary artery disease, diabetes, preferably diabetes type II by administering a pharmaceutical composition comprising an agent which is able to inhibit ATGL. Also contemplated herein, are compositions comprising one or more ATGL-inhibiting agents optionally in combination with one or more lipase inhibitors or inhibitors of inflammatory cytokines.


Find Patent Forward Citations

Loading…